Experienced leadership uniquely positioned to deliver our vision

Our team brings decades of experience and cutting-edge knowledge to the forefront in discovering and developing leading-edge medicines. Collectively, we are dedicated to developing novel therapies with the potential to transform the lives of patients living with cancer.

Our Leadership

Board of Directors

Vlad Coric, MD

CEO, Biohaven Ltd.

John Childs, MBA

Chairman & CEO,
JW Childs Associates L.P.

Larry Feinberg, MBA

Managing Partner, Oracle Investment Management Inc.

Aleksander Rabodzey

Managing Director, Suvretta Capital Management

Brian Lestini, MD, PhD

Chief Executive Officer

Scientific Advisory Board

Manmeet Ahluwalia, MD, FACP, MBA

Chief of Solid Tumor Medical Oncology, Deputy Director and Chief Scientific Officer, Miami Cancer Institute

Daniel Cahill, MD, PhD

Professor, Neurosurgery & Oncology, Harvard Medical
Director of Neuro-Oncology, Massachusetts General Hospital

Moses Chao, PhD

Professor, NYU Langone Medical Center

Timothy Cloughsey, MD

Director, Neuro-Oncology Program at UCLA Medical; Professor of Neurology

George Demetri, MD

Professor, Harvard, Dana Farber; Director of Sarcoma Center
BOD & SAB, Blueprint Medicines

Lori Kunkel, MD

Former CMO & BOD, LoxoOncology; Former CMO, Pharmacyclics
BOD/SAB, Elevation, Rain, Maverick, Nurix, Curis

Michael Lim, MD

Chair of Neurosurgery at Stanford Medicine; former professor of neurosurgery & oncology, Johns Hopkins

David Reardon, MD

Former President of the Society for Neuro-Oncology
Director of Center for Neuro-Oncology, DFCI

John Sampson, MD, PhD, MBA, MHSc

Professor & former Chair of Neurosurgery, Duke University
Member, National Academy of Medicine

Dave Solit, MD

Geoffrey Beene Chair; Director, Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center

Katherine Warren, MD

Clinical Director of Pediatric Neuro-Oncology, Boston Children’s/DFCI; former Head of Pediatric Neuro-Oncology Group, National Cancer Institute